Tracer library / [177Lu]Lu-DOTA-hG250

[177Lu]Lu-DOTA-hG250

Also written as [Lu-177]Lu-DOTA-hG250

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 0

Renal cell carcinoma

What it is

Compound class: DOTA-conjugated monoclonal antibody (girentuximab, hG250)
Target / mechanism: Carbonic anhydrase IX (CAIX) PMID 38948062
Clinical application: Advanced clear cell renal cell carcinoma (ccRCC) PMID 38948062
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-hG250, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38948062. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38948062: 'DOTA-hG250'. Stage set/updated at stage 39 from PMID 38948062: 'the biodistribution of [177Lu]Lu-DOTA-hG250 was investigated in BALB/cAnNRj mice bearing Renca-CAIX or CT26-CAIX tumors'.